Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 2371 AL 2385

Post-marketing safety concerns with foscarbidopa/foslevodopa: A pharmacovigilance study with disproportionality analysis based on FAERS

Peng Y, Ding A, Zhang S, Kong F, Wu L, Sun W, Sun Z, Zheng X, Xi Y.

Medicine (Baltimore). 2026 May 15;105(20):e48874. doi: 10.1097/MD.0000000000048874.

Unlocking a Novel Therapeutic Modality: Low-Intensity Transcranial Ultrasound as a Key to CNS Treatment - A Bibliometric and Systematic Review

Qiao F, Guo Y, Dong Y, Song K, Yan B, Zhou J.

J Cent Nerv Syst Dis. 2026 Jan 28;18:11795735261415705. doi: 10.1177/11795735261415705. eCollection 2026.

Protein S-sulfhydration: Mechanisms and therapeutic implications in Alzheimer's disease and Parkinson's disease

Guo J, Shi C, Yu C, Wang Y, He M.

Free Radic Biol Med. 2026 Mar 16;246:431-441. doi: 10.1016/j.freeradbiomed.2026.01.033. Epub 2026 Jan 20.

Impact of Mobility Loss on Independence and Psychosocial Wellbeing in People With Parkinson's Disease and Carers: A Meta-Ethnography

Hanrahan M, Wilson C, Rochester L, Keogh A, Mc Ardle R, Brittain K.

J Geriatr Psychiatry Neurol. 2026 Jan 7:8919887251414664. doi: 10.1177/08919887251414664. Online ahead of print.

Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders

Zavala-Medina LC, Salas-Leiva JS, Villegas-Mercado CE, Arreguín-Cano JA, Soto-Barreras U, Santana-Delgado SA, Larrinua-Pacheco AD, García-Vega MF, Bermúdez M.

Microorganisms. 2026 Jan 8;14(1):143. doi: 10.3390/microorganisms14010143.

Plant-derived neuroprotective compounds and nanoformulations targeting Parkinson's disease: a semi-systematic review of mechanisms and therapeutic potential

Saraswathi S, Venkataravanappa JT, Nambiar C, Saji S, Kori V, Murthy MN, Somanna P, Sv SB, Sreeramulu AK, Dayalan A, Mohan SP, Murthy CDS.

Metab Brain Dis. 2026 May 19;41(1):101. doi: 10.1007/s11011-026-01868-y.

Exosomal Cargoes Derived from Neural Stem Cell: A New Strategy of Parkinson's Disease Treatment

Tarbali S, Dadkhah M, Payandeh Z.

Mol Neurobiol. 2026 Jan 3;63(1):339. doi: 10.1007/s12035-025-05637-3.

Computational Modeling of Parkinson's Disease Across Scales: From Mechanisms to Biomarkers, Drug Discovery, and Personalized Therapies

Nair SS, Guha A, Chakravarthy S, Shaikh AG.

Brain Sci. 2026 Jan 31;16(2):175. doi: 10.3390/brainsci16020175.

The Influence of Gut Microbiome on Alpha-Synuclein Aggregation: Implications for Parkinson's Disease Pathogenesis

Sain M, Rani S, Singh SP, Pothal P, Yadav S, Suttee A, Kumar A, Kumar S, Ranawat P, Singh G, Barnwal RP.

Mol Neurobiol. 2026 May 19;63(1):639. doi: 10.1007/s12035-026-05917-6.

Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders

Zhang Z, Somerville EN, Fang ZH, Liu L, Asayesh F, Ahmad J, Amiri S, Teferra M, Dodet P, Arnulf I, Hu MTM, Desautels A, Dauvilliers Y, Aktan-Süzgün M, Ibrahim A, Stefani A, Högl B, Gaig C, Montini A, Maya G, Iranzo A, Serradell M, Gigli GL, Valente M, Janes F, Bernardini A, Sonka K, Kemlink D, Dusek P, Sommerauer M, Röttgen S, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Plazzi G, Biscarini F, Antelmi E, De Cock VC, Terzaghi M, Fiamingo G, Heidbreder A, Ferini-Strambi L, Ostrozovicova M, Skorvanek M, Kulcsarova K, Buskova J, Abril B, Orso B, Mattioli P, Arnaldi D, Boeve BF, Ju YE, Ross OA, Wu SY, Lee J, Prilutsky D, Blauwendraat C, Leonard H, Postuma RB, Rouleau GA, Gan-Or Z.

medRxiv [Preprint]. 2026 Feb 5:2026.02.05.26345599. doi: 10.64898/2026.02.05.26345599.

Utilizing Intraindividual Cognitive Variability to Predict Early Neuronal Synuclein Disease Progression

Combs HL, Kurth R, Nair A, York MK, Weintraub D, Lafontant DE, Caspell-Garcia C; Parkinson’s Progression Markers Initiative.

medRxiv [Preprint]. 2026 May 1:2025.10.21.25338482. doi: 10.1101/2025.10.21.25338482.

Complement Dysregulation During the Early Phases of Synucleinopathy

Khan H, Gifford M, Kordbacheh A, Bury A, Panoushek S, Cole-Strauss A, Kemp CJ, Luk KC, Steece-Collier K, Kuhn NC, Kanaan NM, Sortwell CE, Patterson JR, Benskey MJ.

bioRxiv [Preprint]. 2026 Apr 30:2026.04.27.720696. doi: 10.64898/2026.04.27.720696.

Neuroanatomy of substantia nigra and ventral tegmental area dopaminergic, and dorsal raphe serotonergic circuits in the human brain using T1-weighted and diffusion magnetic resonance imaging: A morphometric pilot study with estimate of reliability

Toppa PH, Rushmore RJ, Haggerty K, Papadimitriou G, Dougherty D, Kubicki M, González-Mora JL, Pallanti S, Castañeyra-Perdomo A, Yeterian E, Makris N.

bioRxiv [Preprint]. 2026 Feb 13:2026.02.12.705574. doi: 10.64898/2026.02.12.705574.

Neuronal Cell-Cycle Re-entry Defines Divergent Outcomes Through Replication-Dependent DNA Damage in ALS

Plessis-Belair J, Sher RB.

bioRxiv [Preprint]. 2026 Feb 16:2026.02.13.705790. doi: 10.64898/2026.02.13.705790.

Janus kinase 2 regulates Nurr1 protein stability in dopaminergic neurons of the aging midbrain

Jang Y, Kim YH, Jeon J, Cha Y, Lopes C, Jung JH, Oh E, Park Y, Ko C, Hyeon B, Leblanc P, Kim KS.

bioRxiv [Preprint]. 2026 Mar 23:2026.03.19.712974. doi: 10.64898/2026.03.19.712974.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias